Medroxyprogesterone Acetate for Abnormal Uterine Bleeding
Critical FDA Contraindication
Injectable medroxyprogesterone acetate (Depo-Provera) is explicitly NOT recommended for abnormal uterine bleeding or dysfunctional uterine bleeding due to its prolonged action and unpredictable withdrawal bleeding timing; oral therapy is the appropriate formulation for this indication. 1
Recommended Oral Dosing Regimens
Standard Cyclic Regimen (First-Line)
Administer oral medroxyprogesterone acetate 10–20 mg daily for 10–14 days per month (typically days 16–25 of the menstrual cycle) for women with ovulatory dysfunction-related abnormal uterine bleeding. 2, 3
The 10-day protocol (days 16–25) is superior to the 15-day protocol (days 11–25) for achieving menstrual cycle regularity and stopping abnormal bleeding, with 3 cycles typically sufficient to achieve bleeding cessation. 4
This cyclic progestin regimen reduces menstrual blood loss by approximately 87% in women with heavy cyclic bleeding. 5
Acute Heavy Bleeding Protocol (Adolescents/Severe Cases)
For hospitalized patients with excessive acute bleeding and anemia, administer a loading dose of 60–120 mg total on day 1, followed by 20 mg daily for 10 days. 6
This high-dose regimen stops bleeding within 24 hours in 25% of patients, with 75% achieving cessation within 4 days. 6
Bleeding cessation time correlates inversely with initial hemoglobin levels (lower hemoglobin = longer time to stop bleeding). 6
Patient Selection Factors
Predictors of Treatment Satisfaction
Age ≥35 years (odds ratio 2.67) and desire for uterine conservation (odds ratio 1.36) predict higher satisfaction with medroxyprogesterone acetate therapy. 2
Prior tubal sterilization (odds ratio 0.52) and high perceived importance of definitive bleeding resolution (odds ratio 0.69) predict lower satisfaction; these patients may be better candidates for surgical management or levonorgestrel-IUD. 2
Approximately 57% of patients completing 3 months of therapy report satisfaction with medroxyprogesterone acetate treatment. 2
Superior Alternative: Levonorgestrel-IUD
The levonorgestrel-releasing intrauterine device is more effective than oral medroxyprogesterone acetate, reducing menstrual blood loss by 71–95% versus 75% with oral progestins, with higher patient satisfaction and fewer side effects. 7, 5
The LNG-IUD is the only progestin intrauterine device specifically evaluated for abnormal uterine bleeding treatment and achieves efficacy comparable to endometrial ablation. 5
Critical Pre-Treatment Requirements
Mandatory Diagnostic Workup
Perform pregnancy testing (β-hCG) in all reproductive-age women before initiating therapy, regardless of sexual history or contraceptive use. 8, 9
Do NOT initiate hormonal therapy before obtaining transvaginal ultrasound in women with intermenstrual bleeding, as treatment can mask underlying structural lesions (polyps, fibroids, hyperplasia, malignancy). 9
Measure thyroid-stimulating hormone and prolactin levels to exclude hypothyroidism and hyperprolactinemia as contributors. 8, 9
Order complete blood count with platelets to assess for anemia and thrombocytopenia. 8
Structural Cause Exclusion
Combined transvaginal and transabdominal ultrasound with Doppler is the first-line imaging study to identify polyps, adenomyosis, leiomyomas, and endometrial pathology before starting medical therapy. 9
If ultrasound findings are indeterminate or bleeding persists despite treatment, perform hysteroscopy to visualize focal lesions potentially missed by endometrial sampling. 10, 5
Special Population Considerations
Cardiovascular Disease Patients
In patients with cardiovascular disease or post-spontaneous coronary artery dissection, the levonorgestrel-IUD is strongly preferred over oral medroxyprogesterone acetate due to minimal systemic absorption. 5
Systemic hormonal therapies including oral progestins are relatively contraindicated in cardiovascular disease and require careful clinical judgment before use. 5
Anticoagulation Therapy
For patients on anticoagulation (70% experience heavy menstrual bleeding), reassess the indication for ongoing antiplatelet therapy and discontinue if appropriate before initiating treatment. 8, 9
Progestin-eluting IUDs are preferred over oral therapy in anticoagulated patients due to minimal systemic absorption. 5
Treatment Failure Management
If bleeding persists after 3–6 months of adequate medical therapy, perform further investigation with imaging or hysteroscopy to exclude structural lesions. 10, 5
Refer to gynecology when medical management fails, endometrial sampling shows hyperplasia or malignancy, or postmenopausal bleeding occurs with endometrial thickness ≥4 mm. 9
Consider endometrial ablation or hysterectomy for definitive management when medical therapy fails or is contraindicated. 10, 5
Common Pitfalls to Avoid
Never use injectable depot medroxyprogesterone acetate for abnormal uterine bleeding—only oral formulations are appropriate for this indication per FDA labeling. 1
Do not prescribe oral progestins without first ruling out pregnancy, structural lesions, and endocrine abnormalities through appropriate testing and imaging. 8, 9
Avoid relying solely on endometrial biopsy to exclude focal lesions; saline infusion sonohysterography has 96–100% sensitivity for uterine pathology. 9
Remember that up to 20% of patients on progestogen therapy may still ovulate, requiring assessment for non-hormonal contraception needs. 5